| MeSH term | MeSH ID | Detail |
|---|---|---|
| Body Weight | D001835 | 333 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Hemolysis | D006461 | 131 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Insulin Resistance | D007333 | 99 associated lipids |
| Hypercholesterolemia | D006937 | 91 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (2)
- Clin. Infect. Dis. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (2)
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Cosme A et al. | Antimicrobial susceptibility testing before first-line treatment for infection in patients with dual or triple antibiotic resistance. | 2017 | World J. Gastroenterol. | pmid:28566898 |
| Keshavarz AA et al. | Omeprazole-based triple therapy with low-versus high-dose of clarithromycin plus amoxicillin for H pylori eradication in Iranian population. | 2007 | World J. Gastroenterol. | pmid:17352026 |
| Si JM et al. | Quality of gastric ulcer healing evaluated by endoscopic ultrasonography. | 2005 | World J. Gastroenterol. | pmid:15948255 |
| Hagiwara T et al. | Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection. | 2007 | World J. Gastroenterol. | pmid:17657838 |
| Sanches BS et al. | Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil: A national survey. | 2016 | World J. Gastroenterol. | pmid:27672279 |
| Huang JQ et al. | Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. | 2005 | World J. Gastroenterol. | pmid:15884111 |
| Robles-Jara C et al. | Is a 7-day Helicobater pylori treatment enough for eradication and inactivation of gastric inflammatory activity? | 2008 | World J. Gastroenterol. | pmid:18473407 |
| Koussoulas V et al. | Evidence for the role of gastric mucosa at the secretion of soluble triggering receptor expressed on myeloid cells (strem-1) in peptic ulcer disease. | 2007 | World J. Gastroenterol. | pmid:17729416 |
| Hwang JJ et al. | Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease. | 2015 | World J. Gastroenterol. | pmid:25945019 |
| Gumurdulu Y et al. | Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. | 2004 | World J. Gastroenterol. | pmid:14991935 |
| Guo CY et al. | Clinical evaluation of four one-week triple therapy regimens in eradicating Helicobacter pylori infection. | 2004 | World J. Gastroenterol. | pmid:14991953 |
| Mirbagheri SA et al. | Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: a comparative three-armed randomized clinical trial. | 2006 | World J. Gastroenterol. | pmid:16937475 |
| Lin LC et al. | Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials. | 2016 | World J. Gastroenterol. | pmid:27340362 |
| Ching SS et al. | Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital. | 2008 | World J. Gastroenterol. | pmid:18609709 |
| Trifan A et al. | Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication. | 2013 | World J. Gastroenterol. | pmid:24259981 |
| Matta AJ et al. | Punctual mutations in gene of clarithromycin-resistant in Colombian populations. | 2018 | World J. Gastroenterol. | pmid:29662291 |
| Lee HJ et al. | Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. | 2015 | World J. Gastroenterol. | pmid:25574111 |
| Buzás GM and Józan J | First-line eradication of H pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2004. | 2006 | World J. Gastroenterol. | pmid:16981260 |
| Babic Z et al. | Increased activity of Pgp multidrug transporter in patients with Helicobacter pylori infection. | 2005 | World J. Gastroenterol. | pmid:15884110 |
| Ji F et al. | Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial. | 2006 | World J. Gastroenterol. | pmid:16586550 |
| Zhou Q et al. | Drug utilization of clarithromycin for gastrointestinal disease treatment. | 2008 | World J. Gastroenterol. | pmid:18932287 |
| Sereni G et al. | Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection. | 2012 | World J. Gastroenterol. | pmid:22969227 |
| Isomoto H et al. | Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. | 2005 | World J. Gastroenterol. | pmid:15786539 |
| Wang HH et al. | One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy. | 2005 | World J. Gastroenterol. | pmid:15786549 |
| Aydemir S et al. | Helicobacter pylori infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin. | 2005 | World J. Gastroenterol. | pmid:15682477 |
| Sugimoto M and Furuta T | Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. | 2014 | World J. Gastroenterol. | pmid:24914361 |
| Heo J and Jeon SW | Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance. | 2014 | World J. Gastroenterol. | pmid:24914324 |
| Sun WH et al. | Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients. | 2005 | World J. Gastroenterol. | pmid:15832421 |
| Wu IT et al. | Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan. | 2015 | World J. Gastroenterol. | pmid:26457027 |
| Chen KY et al. | Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial. | 2015 | World J. Gastroenterol. | pmid:26420970 |
| Hwang JJ et al. | Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication. | 2015 | World J. Gastroenterol. | pmid:26401089 |
| Sakurai K et al. | Comparative study: Vonoprazan and proton pump inhibitors in eradication therapy. | 2017 | World J. Gastroenterol. | pmid:28216974 |
| Onyekwere CA et al. | Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: report of an efficacy study. | 2014 | World J. Gastroenterol. | pmid:24707145 |
| Wu JY et al. | Detection of genotypic clarithromycin-resistant Helicobacter pylori by string tests. | 2014 | World J. Gastroenterol. | pmid:24695835 |
| Gao XZ et al. | Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. | 2010 | World J. Gastroenterol. | pmid:20818821 |
| Salimi A et al. | Toxicity of macrolide antibiotics on isolated heart mitochondria: a justification for their cardiotoxic adverse effect. | 2016 | Xenobiotica | pmid:26068526 |
| Pan W et al. | Effects of clopidogrel and clarithromycin on the disposition of sibutramine and its active metabolites M1 and M2 in relation to CYP2B6*6 polymorphism. | 2013 | Xenobiotica | pmid:22830954 |
| Kanayama N et al. | Drug-drug interactions in the metabolism of imidafenacin: role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes. | 2007 | Xenobiotica | pmid:17484517 |
| Burt HJ et al. | IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4. | 2010 | Xenobiotica | pmid:20230210 |
| Kubo JI et al. | Pharmacokinetic evaluation of high pulmonary disposition of clarithromycin after systemic administration. | 2002 | Xenobiotica | pmid:12419017 |
| Yamamoto T et al. | Prediction of oral clearance from in vitro metabolic data using recombinant CYPs: comparison among well-stirred, parallel-tube, distributed and dispersion models. | 2005 | Xenobiotica | pmid:16192112 |
| Niioka T | Clinical usefulness of limited sampling strategies for estimating AUC of proton pump inhibitors. | 2011 | Yakugaku Zasshi | pmid:21372537 |
| Suzuki A et al. | [Clinical efficacy of kanamycin for Mycobacterium avium complex disease]. | 2008 | Yakugaku Zasshi | pmid:18311066 |
| Matsuo R et al. | [Bitterness of the mixture of clarithromycin dry syrup and carbocisteine preparation--difference between brand name and generic drugs]. | 2008 | Yakugaku Zasshi | pmid:18311069 |
| Omura S et al. | [Research and development of clarithromycin]. | 1992 | Yakugaku Zasshi | pmid:1469609 |
| Vakil N | Treatment of H. pylori infection: the reality. | 1998 Mar-Apr | Yale J Biol Med | pmid:10378357 |
| Wang J et al. | [Different concentrations of clarithromycin ophthalmic gel for rabbits corneal ulcers induced by Staphylococcus aureus]. | 2008 | Yan Ke Xue Bao | pmid:18709951 |
| Qin LH and Tang X | [Preparation and evaluation of clarithromycin emulsion for injection]. | 2006 | Yao Xue Xue Bao | pmid:17184111 |
| Zhang T et al. | [Preparation and evaluation of enteric-coated and taste masking clarithromycin granules]. | 2011 | Yao Xue Xue Bao | pmid:22375429 |
| Ma HL et al. | [Polarographic catalytic wave of clarithromycin and its applications]. | 2004 | Yao Xue Xue Bao | pmid:15700824 |